Novo Nordisk’s Wegovy (semaglutide 2.4 mg) has shown positive results in treating metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis in a Phase 3 trial. The drug demonstrated significant improvement in liver fibrosis compared to placebo, potentially paving the way for regulatory approval in the US and EU in the first half of 2025.
A doctor specializing in alcohol-related liver diseases has launched a scathing critique of businessmen promoting the alcohol industry, arguing that no amount of alcohol is safe and that discussions normalizing drinking are harmful. He cites scientific research linking alcohol to numerous health risks and calls for stricter regulations and better public education on the dangers of alcohol.
PGI Chandigarh has launched a new ‘Metabolic Clinic’ to provide integrated care to patients with chronic liver disease and metabolic risk factors such as diabetes and obesity. The clinic aims to offer one-stop management of these conditions, facilitating patient convenience and improving outcomes.
